Rupatadine inhibits colorectal cancer cell proliferation through the PIP5K1A/Akt/CDK2 pathway

Background: Phosphatidylinositol-4-phosphate 5 -kinase type 1 alpha (PIP5K1A) acts upstream of the Akt regulatory pathway and is abnormally expressed in many types of malignancies. However, the role and mechanism of PIP5K1A in colorectal cancer (CRC) have not yet been reported. In this study, we aimed to determine the association between PIP5K1A and progression of CRC and assess the efficacy and mechanism by which rupatadine targets PIP5K1A. Methods: Firstly, expression and function of PIP5K1A in CRC were investigated by human colon cancer tissue chip analysis and cell proliferation assay. Next, rupatadine was screened by computational screening and cytotoxicity assay and interactions between PIP5K1A and rupatadine assessed by kinase activity detection assay and bio-layer interferometry analysis. Next, rupatadine 's anti -tumor effect was evaluated by in vivo and in vitro pharmacodynamic assays. Finally, rupatadine 's anti -tumor mechanism was explored by quantitative real -time reversetranscription polymerase chain reaction, western blot, and immunofluorescence. Results: We found that PIP5K1A exerts tumor-promoting effects as a proto-oncogene in CRC and aberrant PIP5K1A expression correlates with CRC malignancy. We also found that rupatadine down-regulates cyclindependent kinase 2 and cyclin D1 protein expression by inhibiting the PIP5K1A/Akt/GSK-3I3 pathway, induces cell cycle arrest, and inhibits CRC cell proliferation in vitro and in vivo. Conclusions: PIP5K1A is a potential drug target for treating CRC. Rupatadine, which targets PIP5K1A, could serve as a new option for treating CRC, its therapeutic mechanism being related to regulation of the Akt/GSK-3I3 signaling pathway.